Low-Dose ATG/GCSF in Established Type 1 Diabetes: A Five-Year Follow-up Report

Previously, we demonstrated low-dose antithymocyte globulin (ATG) and granulocyte colony-stimulating factor (GCSF) immunotherapy preserved C-peptide for 2 years in a pilot study of patients with established type 1 diabetes (n = 25). Here, we evaluated the long-term outcomes of ATG/GCSF in study part...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Diabetes
Autori principali: Lin, Andrea, Mack, Jasmine A., Bruggeman, Brittany, Jacobsen, Laura M., Posgai, Amanda L., Wasserfall, Clive H., Brusko, Todd M., Atkinson, Mark A., Gitelman, Stephen E., Gottlieb, Peter A., Gurka, Matthew J., Mathews, Clayton E., Schatz, Desmond A., Haller, Michael J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Diabetes Association 2021
Soggetti:
Immunology and Transplantation
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8173803/
https://ncbi.nlm.nih.gov/pubmed/33632742
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/db20-1103
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi